Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,066 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG. Berger J, et al. Among authors: berger mg. Clin Pharmacokinet. 2019 Apr;58(4):469-482. doi: 10.1007/s40262-018-0708-8. Clin Pharmacokinet. 2019. PMID: 30128966 Clinical Trial.
The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.
Berger J, Stirnemann J, Bourgne C, Pereira B, Pigeon P, Heraoui D, Froissart R, Rapatel C, Rose C, Belmatoug N, Berger MG. Berger J, et al. Among authors: berger mg. Br J Haematol. 2012 Apr;157(2):274-7. doi: 10.1111/j.1365-2141.2011.08989.x. Epub 2012 Jan 9. Br J Haematol. 2012. PMID: 22224474 Free article. Clinical Trial. No abstract available.
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.
Raskovalova T, Deegan PB, Mistry PK, Pavlova E, Yang R, Zimran A, Berger J, Bourgne C, Pereira B, Labarère J, Berger MG. Raskovalova T, et al. Among authors: berger j, berger mg. Haematologica. 2021 Feb 1;106(2):437-445. doi: 10.3324/haematol.2019.236083. Haematologica. 2021. PMID: 32001533 Free PMC article.
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells.
Berger MG, Lebecque B, Tassin T, Dannus LT, Berger J, Soucal M, Guerci A, Cony-Makhoul P, Johnson H, Etienne G, Guyotat D, Gagnieu MC, Pereira B, Saugues S, Tournilhac O, Hermet E, Bourgne C. Berger MG, et al. Among authors: berger j. Sci Rep. 2021 Mar 17;11(1):6187. doi: 10.1038/s41598-021-85734-0. Sci Rep. 2021. PMID: 33731863 Free PMC article.
Measurement of imatinib uptake by flow cytometry.
Bourgne C, Bamdad M, Janel A, Libert F, Gagnieu MC, Rapatel C, Pigeon P, Pereira S, Hermet E, Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, Boiret-Dupré N, Berger MG. Bourgne C, et al. Among authors: berger j, berger mg. Cytometry A. 2012 Nov;81(11):996-1004. doi: 10.1002/cyto.a.22118. Epub 2012 Aug 28. Cytometry A. 2012. PMID: 22930640 Free article.
Bone marrow hematons: An access point to the human hematopoietic niche.
Janel A, Berger J, Bourgne C, Lemal R, Boiret-Dupré N, Dubois-Galopin F, Déchelotte P, Bothorel C, Hermet E, Chabi S, Bay JO, Lambert C, Pereira B, Pflumio F, Haddad R, Berger MG. Janel A, et al. Among authors: berger j, berger mg. Am J Hematol. 2017 Oct;92(10):1020-1031. doi: 10.1002/ajh.24830. Epub 2017 Jul 29. Am J Hematol. 2017. PMID: 28639326 Free article.
The chronic lymphocytic leukemia clone disrupts the bone marrow microenvironment.
Janel A, Dubois-Galopin F, Bourgne C, Berger J, Tarte K, Boiret-Dupré N, Boisgard S, Verrelle P, Déchelotte P, Tournilhac O, Berger MG. Janel A, et al. Among authors: berger j, berger mg. Stem Cells Dev. 2014 Dec 15;23(24):2972-82. doi: 10.1089/scd.2014.0229. Stem Cells Dev. 2014. PMID: 25055118
4,066 results